Noona Healthcare has appointed Emmanuel Blin to the position of Chairman of the Board as of 18.10.2017. He will work closely with Noona management and board members to implement the company’s growth strategy and internationalization plans.
Emmanuel Blin has an extensive background in the pharmaceutical industry that spans multiple positions across the globe. After a global career in BMS that included roles in CEE, France, Japan, and the US, he became SVP of BMS and co headed its commercial organization. Emmanuel Blin has also subsequently been appointed Chief Strategy Officer for the company. He became deeply involved in oncology over the last 4 years as BMS began gearing up its Immuno oncology franchise.
“I have always strongly felt the importance of working in cancer treatment development. Medicine has evolved considerably in recent years, however the use of patient-reported outcomes (PROs) in cancer research and treatment decisions has not developed in-step. Relatively few cancer clinics use technology to assist in systematic follow ups on patient wellbeing between treatments. The ASCO conference in Chicago last summer was a tipping point, as research published during the conference demonstrated the potential for PROs technologies to improve patient survival rates by many months. Professor Ethan Basch, the researcher from the University of North Carolina who presented his findings at the conference is a pioneer on the subject and is a key Noona advisor,” says Emmanuel Blin.
”Our vision is now to define new standards for PROs in Oncology. Noona is the first modern PROs service that places patient needs first. Hundreds of patients from different countries have contributed to its development over the past 4 years. Noona has helped cancer patients receive treatments more quickly and has helped care teams identify potentially dangerous side effects and relapses at much earlier dates. Personalized patient wellbeing reporting can assist doctors in prescribing optimal medication dosages and planning supporting care, which all serve to improve the effectiveness of treatments. From the perspective of researchers, the pharmaceutical industry, health authorities, and customers, Noona offers unique insights into the effectiveness of different treatments and potential associated side effects. In addition, preventive care helps reduce emergency room visits and hospitalization days, further lowering the cost of healthcare,” continues Emmanuel Blin.
“We have created a great product with the help of patients and our customers over the past 4 years. We are extremely fortunate to welcome Emmanuel onto the Noona team. With his help, we will work with partners and develop a business strategy that will position Noona at the fulcrum of the global Oncology ecosystem. We additionally have three venture capital firms on our board with extensive track records of bringing health and technology innovations to market. Our aim is for one million of cancer patients to be using Noona globally by 2021,” says Jani Ahonala, Noona CEO.